These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2554602)

  • 21. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18).
    Akasaki M; Takashi T; Kita Y; Tsukada W
    Agents Actions; 1987 Oct; 22(1-2):144-50. PubMed ID: 3318323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-Lys(L18) in rat macrophage cultures and dog synovial fluid.
    Sugawara T; Takada S; Miyamoto M; Nomura M; Kato M
    Inflammation; 1996 Feb; 20(1):43-56. PubMed ID: 8926048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
    Nagao S; Sato K; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental and clinical studies on the effects of synthetic muramyldipeptide derivatives on viral and opportunistic infections.
    Yamamura Y; Ishihara C; Hamada N; Yamamoto K; Azuma I
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):11-4. PubMed ID: 3010013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subacute toxicity of muroctasin in mice and dogs.
    Ono Y; Iwasaki T; Sekiguchi M; Onodera T
    Arzneimittelforschung; 1988 Jul; 38(7A):1024-7. PubMed ID: 3190795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on the stability of muroctasin and degradation products built under extreme conditions.
    Moroi R; Yamazaki K; Hirota T; Watanabe S; Oki M; Toriyama M; Ichinohe A; Kataoka K
    Arzneimittelforschung; 1988 Jul; 38(7A):959-68. PubMed ID: 3190803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Local tolerance of muroctasin injection in rabbits.
    Nakashima K; Jindo T; Nomura M
    Arzneimittelforschung; 1988 Jul; 38(7A):1038-9. PubMed ID: 3190798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of immune responses by muroctasin.
    Akasaki M
    Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer.
    Yanagawa H; Haku T; Takeuchi E; Suzuki Y; Nokihara H; Sone S
    Lung Cancer; 2000 Feb; 27(2):67-73. PubMed ID: 10688489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
    Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
    Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic toxicity of muroctasin in mice.
    Ono Y; Sekiguchi M; Aihara K; Onodera T
    Arzneimittelforschung; 1988 Jul; 38(7A):1028-30. PubMed ID: 3190796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.
    Tsubura E; Nomura T; Niitani H; Osamura S; Okawa T; Tanaka M; Ota K; Nishikawa H; Masaoka T; Fukuoka M
    Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. General pharmacological properties of muroctasin.
    Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
    Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of muramyl dipeptide analog on Salmonella enteritidis infection in beige mice with Chediak-Higashi syndrome.
    Onozuka K; Saito-Taki T; Nakano M
    Microbiol Immunol; 1984; 28(11):1211-21. PubMed ID: 6097802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
    Yoo YC; Saiki I; Sato K; Azuma I
    Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic disposition of 14C-muroctasin in laboratory animals.
    Ono K; Masayasu H; Hashimoto F; Yamada M; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):1009-14. PubMed ID: 3190792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Restoration by N alpha-(N-acetylmuramyl-L-alanyl-D-isoglutamine)-N epsilon-stearoyl-L-lysine from the decomplement state in mice induced by cobra venom factor, followed by acquisition of resistance to bacterial infections].
    Okuda T; Endo N; Zen-Yoji H; Osada Y
    Kansenshogaku Zasshi; 1986 Mar; 60(3):204-9. PubMed ID: 3095445
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro and in vivo augmentation by muroctasin of the production of the third component of complement by murine macrophages.
    Endo N
    Arzneimittelforschung; 1988 Jul; 38(7A):993-6. PubMed ID: 3190805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
    Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
    J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of muroctasin on the activities of drug metabolizing enzymes in liver microsomes of rats.
    Kamataki T; Komori M; Iwasaki M; Ohi H; Kitada M; Miura T; Ono K
    Arzneimittelforschung; 1988 Jul; 38(7A):1019-22. PubMed ID: 3263867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.